Singulex, Inc. Announces Issuance of U.S. Patents for Single Molecule Detection of Protein Biomarkers and Key Biomarker for Cardiac Risk Monitoring

ALAMEDA, Calif.--(BUSINESS WIRE)--Singulex, Inc., the leader in high-definition immunodiagnostic technology, announced today that the U.S. Patent & Trademark Office has issued two patents related to the Company’s Erenna® Technology, for the quantitative measurement of single molecules in complex biological samples. The patented technology enables the Erenna Immunoassay System to integrate single molecule counting into microparticle-based immunoassays that dramatically improve assay sensitivity.